In the past week, XERS stock has gone up by 6.65%, with a monthly gain of 18.24% and a quarterly surge of 20.87%. The volatility ratio for the week is 3.41%, and the volatility levels for the last 30 days are 4.27% for Xeris Biopharma Holdings Inc The simple moving average for the last 20 days is 7.04% for XERS’s stock, with a simple moving average of 35.10% for the last 200 days.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
Moreover, the 36-month beta value for XERS is 1.63. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for XERS is 137.75M and currently, short sellers hold a 7.61% of that float. On February 18, 2025, XERS’s average trading volume was 1.51M shares.
XERS) stock’s latest price update
Xeris Biopharma Holdings Inc (NASDAQ: XERS) has experienced a rise in its stock price by 6.05 compared to its previous closing price of 3.59. However, the company has seen a gain of 6.65% in its stock price over the last five trading days. prnewswire.com reported 2025-01-21 that Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ — The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA’s recently updated Standards of Care in Diabetes—2025 (Standards of Care).1 “Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Piper Sandler repeating the rating for XERS by listing it as a “Neutral.” The predicted price for XERS in the upcoming period, according to Piper Sandler is $3 based on the research report published on November 11, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see XERS reach a price target of $5. The rating they have provided for XERS stocks is “Outperform” according to the report published on March 28th, 2024.
Craig Hallum gave a rating of “Buy” to XERS, setting the target price at $4.50 in the report published on August 28th of the previous year.
XERS Trading at 9.49% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.62% of loss for the given period.
Volatility was left at 4.27%, however, over the last 30 days, the volatility rate increased by 3.41%, as shares surge +15.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.51% upper at present.
During the last 5 trading sessions, XERS rose by +3.95%, which changed the moving average for the period of 200-days by +112.05% in comparison to the 20-day moving average, which settled at $3.55. In addition, Xeris Biopharma Holdings Inc saw 12.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from Schmid John P., who purchase 4,515 shares at the price of $2.25 back on Aug 12 ’24. After this action, Schmid John P. now owns 25,200 shares of Xeris Biopharma Holdings Inc, valued at $10,147 using the latest closing price.
Schmid John P., the Director of Xeris Biopharma Holdings Inc, purchase 4,285 shares at $2.37 during a trade that took place back on Aug 09 ’24, which means that Schmid John P. is holding 20,685 shares at $10,134 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.24 for the present operating margin
- 0.77 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.34. The total capital return value is set at -0.2. Equity return is now at value -617.16, with -19.45 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.12. The debt to equity ratio resting at -9.57. The interest coverage ratio of the stock is -1.52.
Currently, EBITDA for the company is -23.73 million with net debt to EBITDA at -9.18. When we switch over and look at the enterprise to sales, we see a ratio of 4.13. The receivables turnover for the company is 4.55for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
To wrap up, the performance of Xeris Biopharma Holdings Inc (XERS) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
